Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

Lawrence E. Feldman, MD, medical oncologist, professor of Medicine, the University of Illinois Cancer Center, discusses the phase 3 LEAP-006 trial (NCT03829319) evaluating lenvatinib (Lenvima) and pembrolizumab (Keytruda) plus chemotherapy in non–small cell lung cancer (NSCLC).

The global, randomized, double-blind, placebo-controlled, 2-part trial is evaluating pembrolizumab plus platinum-based chemotherapy, with or without lenvatinib, in patients with previously untreated metastatic nonsquamous NSCLC. Part 1 featured the safety run-in portion of the trial, and the ongoing part 2 is randomized, double-blind portion of the reaserch.

Data from part 1 of LEAP-006 showed that lenvatinib and pembrolizumab plus chemotherapy was well tolerated, Feldman says. Positive safety data were reported, with less than 3 dose-limiting toxicities occurring in each of the 2 arms of the study, Feldman explains.

The findings on safety and tolerability led to the opening of enrollment part 2 of the study in October 2021. With the part 2 primary end points of progression-free survival and overall survival, investigators will look for some of the antitumor activity observed in part 1 of the trial, Feldman concludes.